Pasritamig Plus Docetaxel Shows Promise in mCRPC Treatment
Metastatic castration-resistant prostate cancer (mCRPC) remains a challenging stage of prostate cancer with limited treatment options. Recent clinical data suggest that combining pasritamig, an investigational bispecific T-cell engager, with docetaxel chemotherapy may offer a new therapeutic approach for patients who have progressed on prior hormonal therapies.
Understanding the Treatment Approach
Pasritamig is designed to target prostate-specific membrane antigen (PSMA) on cancer cells and CD3 on T cells. By binding both targets simultaneously, it redirects T cells to destroy PSMA-expressing cancer cells. Docetaxel, a well-established chemotherapy agent, works by disrupting cell division in rapidly dividing cells, including cancer cells.
The rationale for combining these agents is to harness both immune-mediated killing and direct cytotoxic effects, potentially overcoming limitations of monotherapy approaches in mCRPC.
Clinical Evidence from Phase 1b Study
Data from a phase 1b clinical trial evaluating pasritamig plus docetaxel in mCRPC patients showed promising efficacy and safety signals. The study included patients whose disease had progressed despite prior androgen receptor pathway inhibitors (ARPIs), chemotherapy, and/or lutetium Lu 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy (Lu-177 PSMA RLT).
Early results indicated antitumor activity, with some patients demonstrating reductions in prostate-specific antigen (PSA) levels and radiographic progression-free survival. The combination also demonstrated a manageable safety profile, supporting further investigation in a phase 3 study.
Expert Perspective
Dr. David R. Wise, a genitourinary medical oncologist at NYU Langone Health and associate professor of medicine and urology at the NYU Grossman School of Medicine, has discussed the potential role of this combination. He notes that the phase 1b data provide a foundation for advancing pasritamig plus docetaxel into later-stage clinical development for mCRPC.
What This Means for Patients
For individuals with mCRPC who have exhausted standard hormonal therapies, emerging treatments like pasritamig plus docetaxel represent an area of active research. While not yet approved, the early clinical signals warrant continued study to determine whether this combination can improve outcomes in a broader patient population.
Patients interested in emerging therapies should discuss clinical trial options with their oncology team, particularly those investigating novel immune-engaging strategies combined with established chemotherapy agents.
Looking Ahead
The progression of pasritamig plus docetaxel into a phase 3 study will be critical for establishing its efficacy and safety in mPC. Future research will focus on identifying which patient subgroups may benefit most, optimizing dosing regimens, and evaluating long-term outcomes.
As the field of prostate cancer treatment evolves, combinations that integrate immunotherapy mechanisms with conventional therapies remain a promising avenue for addressing treatment-resistant disease.
This article is based on information from clinical trial discussions and presentations available as of April 2026. For the most current treatment options, patients should consult their healthcare provider and refer to official clinical trial registries such as ClinicalTrials.gov.